

**In the Claims:**

Please cancel claims 30, 31, and 44, without prejudice to the inclusion of the same or different subject matter in a later filed divisional or continuation application. Please amend claims 23 and 46 as shown in the Listing of the Claims section, below.

**Listing of the Claims:**

1.-22. CANCELED

23. (Currently Amended) A method for inducing an anti-tumor response in a human patient suffering from a tumor, which method comprises administering to the patient in the following order:

(a) on the first day of treatment, a first composition comprising from about  $2 \times 10^5$  to  $2.5 \times 10^8$  of at least one of autologous tumor cells or autologous tumor cell equivalents free from any adjuvant;

(b) four to seven days after initiation of the treatment, cyclophosphamide; and

(c) at least one week after initiation of the treatment, a second composition comprising an adjuvant and from about  $2 \times 10^5$  to about  $1 \times 10^7$  of at least one of autologous tumor cells or tumor cell equivalents, wherein said tumor cells or tumor cell equivalents are conjugated to hapten, wherein the hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, N-iodoacetyl-N'-(5-sulfonic 1-naphthyl) ethylene diamine, trinitrobenzenesulfonic acid, fluorescein isothiocyanate, arsenic acid benzene isothiocyanate, sulfanilic acid, arsanilic acid, dinitrobenzene-S-mustard and combinations thereof, wherein said method results in at least one of an anti-tumor response, therapeutic regression of a tumor or prevention of tumor progression.

24. (Previously Presented) The method in claim 23, in which the adjuvant in said step (c) is *Bacille Calmette-Guerin*.

25. (Previously Presented) The method of claim 23, wherein the tumor cells or tumor cell equivalents in said step (a) are haptenized with a hapten selected from the group consisting of dinitrophenyl, trinitrophenyl, N-iodoacetyl-N'-(5-sulfonic 1-naphthyl) ethylene diamine, trinitrobenzenesulfonic acid, fluorescein isothiocyanate, arsenic acid benzene isothiocyanate, sulfanilic acid, arsanilic acid, dinitrobenzene-S-mustard and combinations thereof.

26. (Previously Presented) The method of claim 23, wherein the tumor cells or tumor cell equivalents in said step (a) are a mixture of haptenized and non-haptenized tumor cells or tumor cell equivalents.

27. CANCELED

28. CANCELED

29. (Previously Presented) The method of claim 23, wherein the hapten is dinitrophenyl.

30. CANCELED

31. CANCELED

32. (Previously Presented) The method of claim 23, wherein the tumor cells or tumor cell equivalents originate from a tumor selected from the group consisting of melanoma, ovarian cancer, colon cancer, breast cancer, rectal cancer, lung cancer, kidney cancer, prostate cancer, and leukemia.

33. (Previously Presented) The method of claim 32, wherein the tumor is melanoma.

34. (Previously Presented) The method of claim 32, wherein the tumor is ovarian cancer.

35. (Previously Presented) The method of claim 23, wherein the tumor cell or tumor cell equivalents are rendered incapable of growth or multiplication *in vivo*.

36. (Previously Presented) The method of claim 35, wherein the tumor cell or tumor cell equivalents are rendered incapable of growth or multiplication *in vivo* by irradiation.

37. (Previously Presented) The method of claim 35, wherein the tumor cells or tumor cell equivalents are rendered incapable of growth or multiplication *in vivo* by haptization.

38.-42. CANCELED

43. (Previously Presented) The method of claim 23, wherein the adjuvant in said step (c) is selected from the group consisting of *Bacille Calmette-Guerin*, Q-21, and detoxified endotoxin.

44. CANCELED

45. (Previously Presented) The method of claim 23, wherein the cyclophosphamide is administered 5 to 7 days after administration of the first composition.

46. (Currently Amended) A method for inducing an anti-tumor response in a human patient suffering from a tumor, which method comprises administering to the patient in the following order:

(a) a composition comprising from about  $2 \times 10^5$  to about  $2.5 \times 10^6$  of at least one of tumor cells or tumor cell equivalents per dose, without any adjuvant, wherein the tumor cells or tumor cell equivalents are conjugated to a hapten, and rendered incapable of growth or multiplication *in vivo*;

(b) cyclophosphamide; and

(c) a second composition comprising an adjuvant and from about  $2 \times 10^5$  to about  $2.5 \times 10^6$   $1 \times 10^7$  of at least one of tumor cells or tumor cell equivalents, wherein the tumor cell or tumor cell equivalents are conjugated to a hapten,

wherein the hapten in steps (a) and (c) is the same or different, and is selected from the group consisting of dinitrophenyl, trinitrophenyl, N-iodoacetyl-N'-(5-sulfonic 1-naphthyl) ethylene diamine, trinitrobenzenesulfonic acid, fluorescein isothiocyanate, arsenic acid benzene isothiocyanate, sulfanilic acid, arsanilic acid, dinitrobenzene-S-mustard and combinations thereof, and

wherein said method results in at least one of an anti-tumor response, therapeutic regression of a tumor or prevention of tumor progression.

47. (Previously Presented) The method of claim 46, wherein the hapten in said steps (a) and (c) is dinitrophenyl.

48. (Previously Presented) The method of claim 46, wherein the tumor is melanoma.

49. (Previously Presented) The method of claim 46, wherein the tumor is ovarian cancer.

50. (Previously Presented) The method of claim 46, wherein the adjuvant is selected from the group consisting of *Bacille-Calmette-Guerin*, Q-21, and detoxified endotoxin.

51.-54. CANCELED

55. (Previously Presented) A method for inducing an anti-tumor response in a mammalian patient suffering from a tumor, which, method comprises administering to the patient:

(a) on the first day of treatment, a composition comprising  $2 \times 10^5$  to  $2.5 \times 10^6$  haptenized autologous tumor cells free from any adjuvant;

(b) four to seven days after initiation of the treatment, cyclophosphamide; and

(c) at least one week after initiation of the treatment, a second composition comprising an adjuvant and  $2 \times 10^5$  to  $1 \times 10^7$  haptenized autologous tumor cells

wherein the cells in said steps (a) and (c) are haptenized with dinitrophenyl, and  
wherein said method results in at least one of an anti-tumor response, therapeutic  
regression of a tumor or prevention of tumor progression.

56. (Previously Presented) The method of claim 55, in which the adjuvant in said step  
(c) is *Bacille Calmette-Guerin*.